Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.

Anti-cancer drugs - 1 Oct 2011

Modest Dominik P, Stintzing Sebastian, Laubender Ruediger P, Neumann Jens, Jung Andreas, Giessen Clemens, Haas Michael, Aubele Philipp, Schulz Christoph, Boeck Stefan, Stemmler Hans-Joachim, Kirchner Thomas, Heinemann Volker

Abstract excerpt

This retrospective study investigated the clinical characteristics of patients with metastatic colorectal cancer (mCRC) depending on the KRAS status, thereby differentiating KRAS exon 2 mutations in codon 12 versus codon 13. In total, 273 patients with mCRC receiving first-line therapy were analyzed. One hundred patients were treated within the FIRE-3 trial (FOLFIRI plus cetuximab or bevacizumab), 147 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cetuximab

Share to Genes, ras

Share to Liver Neoplasms

Share to Lymphatic Metastasis

Share to ras Proteins

Source

Identifiers

PMID: 21795973
DOI: 10.1097/CAD.0b013e3283493160

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.PMID 21795973Read ↗

KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.Semantic proximity Read ↗

KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.Semantic proximity Read ↗

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.Semantic proximity Read ↗

Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.Semantic proximity Read ↗

Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.Semantic proximity Read ↗

Clinical relevance of KRAS mutations in codon 13: Where are we?Semantic proximity Read ↗

Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value.Semantic proximity Read ↗

The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.Semantic proximity Read ↗

The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.Semantic proximity Read ↗

Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.Semantic proximity Read ↗

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.